Name | Title | Contact Details |
---|
TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Threshold Pharmaceuticals, Inc. is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
eRAD offers a complete suite of workflow solutions for the imaging industry. Its Meaningful Use-ready RIS, web-based PACS, and multi-site workflow solutions are used by teleradiology businesses, specialty reading groups, multi-site reading groups, hospitals and outpatient imaging centers. With over 300 customers in the US and several other countries, eRAD`s solutions are available as cloud-based hosted solutions, or as in-house enterprise solutions.
RetinaPharma Technologies is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and devastating metabolic diseases with limited treatment options. Aeglea`s lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation. In the second quarter of 2020, the Company initiated a Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria. AGLE-177 has also been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have big impact on the lives of patients and their families.